Assessment of Measurable Residual Disease Using Patient-Specific Markers and Outcomes After HSCT for Myelodysplastic Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol 2024 Jan 17;[EPub Ahead of Print], M Tobiasson, T Pandzic, J Illman, L Nilsson, S Weström, E Ejerblad, G Olesen, A Björklund, A Olsnes Kittang, O Werlenius, F Lorentz, B Rasmussen, J Cammenga, D Weber, C Lindholm, J Wiggh, M Dimitriou, AE Moen, L Yip Lundström, L von Bahr, K Baltzer-Sollander, M Jädersten, S Kytölä, G Walldin, P Ljungman, K Groenbaek, S Mielke, SEW Jacobsen, F Ebeling, L Cavelier, L Smidstrup Friis, I Dybedal, E Hellström-LindbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.